| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/13/2011 | US20110008354 Antibodies to apo-2 receptor polypeptides |
| 01/13/2011 | US20110008353 Identification of astrovirus va1 associated with gastroenteritis in humans |
| 01/13/2011 | US20110008352 Toll-Like Receptor 3 Antagonists |
| 01/13/2011 | US20110008351 Anticomplement polypeptides of ixodes ricinus |
| 01/13/2011 | US20110008350 Extracellular targets for alzheimer's disease |
| 01/13/2011 | US20110008349 Hypoxia Induced Mitogenic Factor |
| 01/13/2011 | US20110008348 Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
| 01/13/2011 | US20110008347 Cancer-related protein kinases |
| 01/13/2011 | US20110008346 Biomarkers for cardiovascular disease |
| 01/13/2011 | US20110008345 Antigen-binding constructs |
| 01/13/2011 | US20110008344 Fusion partner cell line for preparation of hybrid cells expressing human antibodies |
| 01/13/2011 | US20110008343 Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation |
| 01/13/2011 | US20110008342 Compositions of humanized notch fusion proteins and methods of treatment |
| 01/13/2011 | US20110008341 Polypeptides and methods for making the same |
| 01/13/2011 | US20110008340 Anti-properdin antibodies |
| 01/13/2011 | US20110008339 Monoclonal antibody and use thereof |
| 01/13/2011 | US20110008338 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008337 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008336 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008335 Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using NK Cell Potentiating Compounds |
| 01/13/2011 | US20110008334 Nogo-a binding with enhanced affinity and pharmaceutical use thereof |
| 01/13/2011 | US20110008333 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 01/13/2011 | US20110008332 Combination Therapy to Treat Persistent Viral Infections |
| 01/13/2011 | US20110008331 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| 01/13/2011 | US20110008330 Compositions and methods of tolerizing a primate to an antigen |
| 01/13/2011 | US20110008329 Methods of Treating RSV Infections And Related Conditions |
| 01/13/2011 | US20110008328 Method for controlling glucose uptake and insulin sensitivity |
| 01/13/2011 | US20110008327 Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| 01/13/2011 | US20110008326 Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| 01/13/2011 | US20110008325 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008323 Cadherin-11 EC1 Domain Antagonists for Treating Inflammatory Joint Disorders |
| 01/13/2011 | US20110008322 Anti-c35 antibody combination therapies and methods |
| 01/13/2011 | US20110008321 Vectors, Host Cells, and Methods of Production and Uses |
| 01/13/2011 | US20110008320 Further Use of Protein Kinase N Beta |
| 01/13/2011 | US20110008319 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/13/2011 | US20110008318 Toll-like receptor 5 ligands and methods of use |
| 01/13/2011 | US20110008288 Hepatitis c virus inhibitors |
| 01/13/2011 | US20110008282 IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| 01/13/2011 | US20110008280 Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| 01/13/2011 | US20110008279 Methods and Compositions Relating to Adhesins as Adjuvants |
| 01/13/2011 | US20110008256 Monoclonal antibodies that bind or neutralize dengue virus |
| 01/13/2011 | US20110008251 Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses |
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008249 Proteins with high immunoreactivity and method for their production |
| 01/13/2011 | CA2803282A1 Methods for preparing vesicles and formulations produced therefrom |
| 01/13/2011 | CA2767595A1 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| 01/13/2011 | CA2767536A1 Conserved escherichia coli immunogens |
| 01/13/2011 | CA2767442A1 Antibody having anti-cancer activity |
| 01/13/2011 | CA2767392A1 Methods for preparing vesicles and formulations produced therefrom |
| 01/13/2011 | CA2767231A1 Cell-based bioprocessing |
| 01/13/2011 | CA2766996A1 Humanised antibodies to toll-like receptor 2 and uses thereof |
| 01/13/2011 | CA2766907A1 Self replicating rna molecules and uses thereof |
| 01/13/2011 | CA2766737A1 Diagnosis and treatment of autoimmune demyelinating diseases |
| 01/13/2011 | CA2766649A1 Zinc supplementation to increase responsiveness to metalloprotease therapy |
| 01/13/2011 | CA2766608A1 Bi-specific digoxigenin binding antibodies |
| 01/13/2011 | CA2766405A1 Engineered fc regions for site-specific conjugation |
| 01/13/2011 | CA2766285A1 New composition |
| 01/13/2011 | CA2766166A1 Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
| 01/13/2011 | CA2766152A1 Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid |
| 01/13/2011 | CA2765090A1 A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent |
| 01/13/2011 | CA2757543A1 Compositions and methods related to protein a (spa) variants |
| 01/12/2011 | EP2273419A1 Methods of treating and preventing colitis involving IL-13 and NK-T cells |
| 01/12/2011 | EP2273266A1 Parasporin-1 receptor and use thereof |
| 01/12/2011 | EP2272960A1 Human protein NELL2 gene |
| 01/12/2011 | EP2272950A2 Defective influenza virus particles |
| 01/12/2011 | EP2272949A2 Infectious bursal disease virus antigenic isolates and vaccines |
| 01/12/2011 | EP2272874A1 Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
| 01/12/2011 | EP2272873A2 Antibodies against insulin-like growth factor I receptor and uses thereof |
| 01/12/2011 | EP2272870A1 Process for manufacturing immunoglobulins for intravenous administration and other immunoglobulin-like products |
| 01/12/2011 | EP2272869A2 Angiopoietin-2 specific binding agents |
| 01/12/2011 | EP2272868A2 Combination therapy for B cell disorders |
| 01/12/2011 | EP2272861A1 Polyepitope carrier protein |
| 01/12/2011 | EP2272859A2 Immunological herpes simplex virus antigens and methods for use thereof |
| 01/12/2011 | EP2272565A2 Prevention of thrombus formation and/or stabilization |
| 01/12/2011 | EP2272534A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 01/12/2011 | EP2272533A1 Soluble FcyR fusion proteins and methods of use thereof |
| 01/12/2011 | EP2272532A2 Rotavirus vaccine |
| 01/12/2011 | EP2272531A2 Integration of meningococcal conjugate vaccination |
| 01/12/2011 | EP2272530A2 Antigenic Compositions |
| 01/12/2011 | EP2272529A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272528A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272527A2 Combined DNA vaccine and biological modifiers for cancer therapy |
| 01/12/2011 | EP2272526A2 Adjuvant for transcutaneous immunization |
| 01/12/2011 | EP2272525A2 Adjuvant viral particle |
| 01/12/2011 | EP2272502A1 Cryogranules of a liquid composition of an allergen product |
| 01/12/2011 | EP2272497A2 Methods Of Increasing Lymphatic Function |
| 01/12/2011 | EP2272340A1 Botulinum toxin |
| 01/12/2011 | EP2271768A2 Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung |
| 01/12/2011 | EP2271673A2 Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/12/2011 | EP2271672A2 Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/12/2011 | EP2271671A2 Tnf-alpha inhibitors for treating bone loss |
| 01/12/2011 | EP2271664A1 Novel sequences of brachyspira, immunogenic composition, methods for preparation and use thereof |
| 01/12/2011 | EP2271366A1 Antibodies to clostridium difficile spores and uses thereof |
| 01/12/2011 | EP2271365A2 Regulation of fatty acid transporters |
| 01/12/2011 | EP2271364A1 Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology |
| 01/12/2011 | EP2271363A1 Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
| 01/12/2011 | EP2271361A1 Method and vaccine for optimizing the specific immune responses |
| 01/12/2011 | EP2271360A1 Vaccine |
| 01/12/2011 | EP2271359A2 Camptothecin-binding moiety conjugates |